NeuroMetrix, Inc. (the “Company”) (Nasdaq: NURO), a medical device
company focused on the treatment and management of the neurological
complications of diabetes, today announced a national distribution
agreement with DJO Global for the SENSUS™ Pain Management System. SENSUS
is a convenient and wearable non-invasive electrical nerve stimulator
that offers patients a fast-acting, non-narcotic option for relief from
chronic pain. The device is lightweight and can be worn during the day
while remaining active, or at night while sleeping. It is optimally
designed for people with diabetes that suffer from chronic pain. The
most common cause of such pain is painful diabetic neuropathy (PDN),
which affects up to 5 million people in the U.S. alone.
The Recovery Sciences division of DJO is a leading manufacturer and
distributor of electrical stimulation and other orthopedic products used
for pain management, orthopedic rehabilitation, physical therapy,
fitness and sport performance enhancement. It deploys a direct US sales
force. Recovery Sciences will market SENSUS primarily to pain management
and podiatry clinics, as well as in endocrinology, internal medicine,
primary care and neurology clinics. This agreement follows a SENSUS
market pilot conducted in the second half of 2013.
“SENSUS nicely compliments the Recovery Sciences electrotherapy product
offerings for pain management”, said Rick Rioles, Senior Vice President,
Business Development, Recovery Sciences Division, DJO Global. “We
believe that the diabetic pain market represents a growth opportunity
for electrotherapy as it addresses important unmet clinical needs. We
are impressed by the SENSUS technology and its status as the only
transcutaneous electrical nerve stimulator cleared for use during sleep.
We believe it will have strong appeal in our target markets.”
“DJO Global is a leader in the pain management market. The Recovery
Sciences division includes EMPI, which is a long standing premier brand
in the transcutaneous electrical nerve stimulator market. We believe
that the national reach, talent, and subject matter expertise of the
Recovery Sciences sales force will play a key role in accelerating
SENSUS adoption in the US market,” said Shai N. Gozani, M.D., Ph.D.,
President and Chief Executive Officer of NeuroMetrix. “We believe that
this partnership will substantially expand patient access to the
clinical benefits of SENSUS pain therapy.”
About DJO Global, Inc.
DJO Global, Inc. is a leading global provider of high-quality,
orthopedic devices, with a broad range of products used for
rehabilitation, pain management and physical therapy. It also develops,
manufactures and distributes a broad range of surgical reconstructive
implant products. DJO Global is the largest non-surgical orthopedic
rehabilitation device company in the United States and among the largest
globally, as measured by revenues. For more information, please visit http://www.djoglobal.com.
About NeuroMetrix
NeuroMetrix is a medical device company that develops and markets home
use and point-of-care devices for the treatment and management of
chronic pain, peripheral neuropathies, and associated neurological
disorders. The Company is presently focused on diabetic neuropathies,
which affect over 50% of people with diabetes. If left untreated,
diabetic neuropathies trigger foot ulcers that may require amputation
and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company markets the SENSUS™ Pain Management System for treating chronic
pain, focusing on physicians managing patients with painful diabetic
neuropathy. The company also markets the DPNCheck® device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. For more information, please
visit http://www.SENSUSRx.com.
Copyright Business Wire 2014